Cormorant Asset Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Cormorant Asset Management’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-479,506	Closed	-$4.08M	–	93
2021 Q3	$4.08M	Hold	479,506	–	–	0.17%	75
2021 Q2	$7.87M	Sell	479,506 -420,494	-47%	-$8.49M	0.27%	68
2021 Q1	$19.9M	Buy	900,000 +400,000	+80%	+$10.9M	0.44%	52
2020 Q4	$15.5M	Sell	500,000 -100,000	-17%	-$2.53M	0.37%	56
2020 Q3	$12.2M	Buy	+600,000	New	+$10.5M	0.47%	50

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cormorant Asset Management's TCRR Position: Q4 2021 in Review

Cormorant Asset Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 479,506 shares — an estimated $4.08M sold.

Cormorant Asset Management first reported a position in TCRR in Q3 2020 and held it in 5 quarters. The position peaked at $19.9M in Q1 2021. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

Cormorant Asset Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Cormorant Asset Management sold 479,506 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $4.08M.
Cormorant Asset Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Cormorant Asset Management's TCR2 Therapeutics Inc. Common Stock position peaked at $19.9M in Q1 2021.
122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.